Nivolumab led to a greater proportion of patients achieving an ORR and fewer toxic effects than with alternative available chemotherapy regimens for patients with advanced melanoma that has progressed after ipilimumab or ipilimumab and a BRAF inhibitor. This evidence concerns the gene BRAF and melanoma.